MetaMol Diagnostics focuses on advanced diagnostic technologies aimed at improving patient outcomes through precision medicine. Their primary offerings include innovative biomarker discovery and validation processes that leverage cutting-edge analytical techniques. These technologies are designed to identify specific molecular signatures associated with various diseases, enabling more accurate diagnoses and personalized treatment plans. By utilizing high-throughput screening and sophisticated data analysis, MetaMol aims to enhance the understanding of disease mechanisms and facilitate the development of targeted therapies.

In addition to biomarker discovery, MetaMol Diagnostics emphasizes the importance of integrating multi-omics approaches, which combine genomics, proteomics, and metabolomics. This holistic view allows for a comprehensive analysis of biological systems, providing deeper insights into disease progression and treatment responses. The company's commitment to advancing diagnostic capabilities is reflected in their focus on translating scientific research into practical applications that can significantly impact clinical practice and patient care.

United States

A NEW Test to Determine Breast Cancer Risk....A Breakthrough!!!!
Women with lumps in their breasts have to make a difficult decision whether or not to undergo treatment. For these women, a NEW TEST can help in the  assessment of their cancer risk and hugely facilitate their decision-making process. We have studied a protein (called hOPN-c), which serves this purpose. The presence of hOPN-c in a lump indicates an elevated risk for breast cancer down the road, and the more of it is detected the more substantive is the risk. A pathologist can simply apply this test to a biopsy

University of Cincinnati, Cincinnati, Ohio, US

MetaMol Diagnostics

Company Details